Litcius/Paper detail

LBA20 Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors

Matthew P. Goetz, P. Plourde, Daniel G. Stover, Nusayba A. Bagegni, GA Vidal, Adam Brufsky, H. S. Rugo, D.J. Portman, Einav Nili Gal‐Yam

2022Annals of Oncology14 citationsDOI

Topics & Concepts

MedicineMetastatic breast cancerFulvestrantInternal medicineProgression-free survivalClinical endpointGastroenterologyEstrogen receptorBreast cancerOncologyProgressive diseaseCancerGynecologyRandomized controlled trialChemotherapyAdvanced Breast Cancer TherapiesLung Cancer Research Studies
LBA20 Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors | Litcius